Abstract
Q:Many of our staff are anxious to use newer therapies for the treatment of certain common diseases, such as deep vein thrombosis. However, we often feel frustrated because clinical managers and financial administrators disagree on the most beneficial and cost-effective treatments. How might we establish a plan that benefits both groups of people while reducing costs and improving the quality of patient care?.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
